Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,332 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06116110Recruiting
Long-term follow-up after gene therapy treatment
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Gilbert, ArizonaAges 18 years+ - NCT05990465RecruitingPhase 1
LV20.19 CAR T-cells plus pirtobrutinib for relapsed B-cell lymphoma
This trial combines a new type of CAR T-cell therapy (LV20.19) with a targeted pill called pirtobrutinib to treat B-cell lymphomas that have come back or stopped responding. The goal is to see if this combination works better than each alone.
Milwaukee, WisconsinAges 18–81 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT05365659RecruitingPhase 1
Testing IKS03 for advanced B-cell lymphoma
This trial tests a new study drug, IKS03, for people with advanced B-cell non-Hodgkin lymphoma that has not responded to at least two prior treatments. The goal is to see if the drug is safe and how well it works.
Baltimore, MarylandAges 18 years+ - NCT05006716RecruitingPhase 1/Phase 2
New treatment for blood cancers that have returned
This trial tests a new pill, tacabrutideg, for blood cancers that have returned or not improved after earlier treatments. It may work for patients who have already tried a type of targeted therapy called a BTK inhibitor.
Birmingham, AlabamaAges 18 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT04139304RecruitingEarly Phase 1
Study of daratumumab with EPOCH for plasmablastic lymphoma
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
Miami, FloridaAges 18 years+ - NCT07731789RecruitingPhase 2
Antibody combo for newly diagnosed follicular lymphoma
This trial tests two antibody medications, tafasitamab and rituximab, as the first treatment for newly diagnosed follicular lymphoma. The goal is to see if this combination can effectively control the lymphoma and potentially reduce the need for more intensive therapies.
Seattle, WashingtonAges 18 years+ - NCT06339255Recruiting
Observational study on CAR-T therapy for lymphoma
This study observes patients with certain lymphomas who are already eligible for standard CAR-T cell therapy in Italy. It aims to gather real-world information about how these treatments work.
MilanAges 18 years+ - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT07545603RecruitingPhase 2
XNW5004 tablets for hard-to-treat follicular lymphoma
This study tests a new tablet called XNW5004 in patients with follicular lymphoma (a type of blood cancer) that has come back or stopped responding after multiple prior treatments. The goal is to see if this drug can help control the cancer in patients who have limited options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06980116RecruitingPhase 1
Finding the right dose of EXS73565 for relapsed B-cell cancers
This study tests a new oral medication (EXS73565) for people with B-cell blood cancers that came back or didn't respond to standard treatments. It aims to find the best dose and check if it's safe and helpful.
TbilisiAges 18 years+ - NCT06822829Recruiting
Study of lymphoma that returned as slow-growing type
This study looks at people whose diffuse large B-cell lymphoma came back as a slower-growing lymphoma. Doctors want to understand how and why this happens, using medical records from diagnosis through follow-up.
Reggio EmiliaAges 18 years+ - NCT06796998RecruitingPhase 2
Epcoritamab for newly diagnosed marginal zone lymphoma
This trial tests a new immunotherapy drug, epcoritamab, for people who have been recently diagnosed with marginal zone lymphoma (MZL) and haven't had treatment yet. The goal is to see if the drug can shrink tumors or control the disease.
Miami, FloridaAges 18 years+ - NCT06745076RecruitingPhase 2
Personalized chemotherapy reduction for advanced Hodgkin lymphoma
This trial tests a personalized approach to using a blood test (ctDNA) to decide how much chemotherapy you need. If you have advanced Hodgkin lymphoma, this study might let you have less chemo if the blood test shows a strong response early on, potentially reducing side effects.
Irvine, CaliforniaAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Birmingham, AlabamaAges 18–75 - NCT06716658RecruitingPhase 2
New targeted drug for certain T/NK-cell lymphomas
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06693830Recruiting
Blood test guided treatment for newly diagnosed DLBCL
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
New York, New YorkAges 18 years+ - NCT06588205Recruiting
Understanding MYC changes in aggressive B-cell lymphomas
This study looks at how changes in the MYC gene affect the outlook for people with certain fast-growing lymphomas, including diffuse large B-cell lymphoma and high-grade B-cell lymphoma. It aims to better understand the tumor environment and how these patients respond to standard chemotherapy.
AlessandriaAges 18–79 - NCT06510361RecruitingPhase 2
Epcoritamab for follicular lymphoma not cured by initial treatment
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
Stanford, CaliforniaAges 18 years+ - NCT06484920RecruitingPhase 2
Pembrolizumab and ATRA for relapsed lymphoma
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
Indianapolis, IndianaAges 18 years+ - NCT06486051RecruitingPhase 2
CAR T-cell therapy for adults with relapsed large B-cell lymphoma
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
Auckland, AucklandAges 18–75 - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Duarte, CaliforniaAges 18 years+
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,332 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.